Skip to contentpdufa.bio

Reproxalap ophthalmic

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA issued a Complete Response Letter for Reproxalap ophthalmic on Mar 16, 2026. 1 FDA decision on record below.

ALDX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Mar 16, 2026 (announced Mar 17, 2026) CRLALDX

Questions

When is Reproxalap ophthalmic's next FDA decision or readout?

No upcoming catalyst is on our calendar for Reproxalap ophthalmic; 1 FDA decision is on record below.

What happened at Reproxalap ophthalmic's most recent FDA decision?

On Mar 16, 2026 the FDA issued a Complete Response Letter. The decision page carries the source document and the measured share-price reaction.

Has Reproxalap ophthalmic been approved by the FDA?

Not in our records. The FDA issued a Complete Response Letter on Mar 16, 2026.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.